

## INTENDED MONITORING

*As medicinal cannabis is an unapproved medicine my patients will be reviewed regularly to ensure efficacy and to manage any adverse events. We suggest a monitoring program similar to opioids will be clinically useful.*

Once established on a dose, a monthly review is recommended as a minimum.

At each review the medical practitioner should ensure the following areas are covered: Symptom Control, Adverse Events, Aberrant Behaviour, Records (SAAR):

- **Symptom Control** - Is the product improving my patient's symptoms? - For example, are they eating better, experiencing less nausea and vomiting, have improved pain management and spasticity or evidence of fewer seizures?
- **Adverse Events** - Are they reporting any side effects? For example, is there any signs of drug-drug interactions that may require adjustment of the product or the other medications?
- **Aberrant Behaviour** - Are there concerns that the patient may be on-selling their product? For example, are they using more than prescribed at any one time?
- **Records** - It is important to keep adequate records, especially as this is an unapproved medicine.